Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| GHRP-6 | LL-37 (Cathelicidin) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. | Research indicates 50-100 mcg daily via subcutaneous injection for immune support. |
| Timing | On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical. | Morning administration preferred for immune support. Topical application directly to wound sites. |
| Cycle Duration | 8-16 week cycles. | 4-8 week cycles. Short-term use preferred due to limited long-term safety data. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates GH release through activation of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) on pituitary somatotrophs. It acts via dual sites — pituitary and hypothalamic — possibly involving regulatory factors beyond GHRH and somatostatin. GHRP-6 also stimulates ghrelin-mediated appetite signaling, increases cortisol and prolactin release, and has demonstrated cytoprotective properties including cardioprotection.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.
8-16 week cycles.
LL-37 is a 37-residue amphipathic helical antimicrobial peptide, the only human cathelicidin, that kills bacteria by forming tetrameric channels that perforate cytoplasmic membranes. Beyond direct antimicrobial activity, it modulates innate immunity through formyl-peptide receptor 2 (FPR2), induces chemotaxis of neutrophils and monocytes, upregulates CXCR4 and IL-8, and neutralizes bacterial endotoxins (LPS). It also promotes wound healing through keratinocyte migration and angiogenesis.
Research indicates 50-100 mcg daily via subcutaneous injection for immune support.
Morning administration preferred for immune support. Topical application directly to wound sites.
4-8 week cycles. Short-term use preferred due to limited long-term safety data.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →